SimInPath 與 Immunotrain 使用情況與統計

SimInPath is a freely-accessible App and represents an Objective Structured Clinical Examination OSCE-like tool for evaluating competences in Pathology: grossing (dissection), Fine Needle Aspiration Cytology by palpation and ultrasound-guided, palpation skills, punch biopsy, and microscopic diagnosis, integrated in modules, simulation-based. It is intended for Pathology teachers and instructors and uses Likert-like checklists designed by Dr. Eduardo Alcaraz-Mateos (contact: edusqo@hotmail.com) in his workshops. The registered data will be solely owned by the user and will not be shared (local storage).
  • Apple App Store
  • 免費版
  • 教育

商店排名

- -

Are you a pathologist looking to enhance your skills and accuracy in Ki-67 immunohistochemistry rating? Look no further than Immunotrain! Our app uses cutting-edge artificial image generation to simulate the estimation of biomarker-positive cells in a given tissue. With Immunotrain, you can practice, learn, and compete against your peers to become the ultimate master of Ki-67 rating. Our leaderboard feature allows you to track your progress and see how you stack up against the best in the field. Immunotrain is the ultimate tool for pathologists who regularly screen Ki-67 or ER/PR immunostainings of tumors. Our app simulates the estimation of the percentage of positive cells in a given tissue by generating artificial images that approximate a set of cells in their color. With Immunotrain, you can practice your rating skills, improve your accuracy, and compete against your peers on the leaderboard. Our app also provides ground truth information to help you learn and make better decisions. Try Immunotrain today and become a master of intuitive immunohistochemistry rating!
  • Apple App Store
  • 免費版
  • 教育

商店排名

- -

SimInPath與 Immunotrain 比較排名

比較過去 28 天的 SimInPath 排名趨勢與 Immunotrain

排名

無可用數據

各國 SimInPath vs. Immunotrain 排名比較

比較過去 28 天的 SimInPath 排名趨勢與 Immunotrain

無可顯示數據

使用我們的免費試用版,與所有網站進行比較

立即開始
SimInPath VS.
Immunotrain

12月 23, 2024